Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.36 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL542029 | 0.83 | — | — | |
| SCHEMBL135585 | 0.82 | POLB (0.43) | POLBATMOPRM1SMN1; SMN2OPRD1 | |
| SCHEMBL18500642 | 0.82 | ALDH1A1 (0.41) | POLBATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL19766 | 0.81 | POLB (0.42) | POLBATMOPRM1SMN1; SMN2OPRD1 | |
| SCHEMBL18768458 | 0.80 | TSHR (0.36) | SMN1; SMN2SLC6A4MEN1KMT2AMAPT | |
| SCHEMBL1815035 | 0.79 | SMN1; SMN2 (0.41) | POLBATMOPRM1SMN1; SMN2OPRD1 | |
| SCHEMBL5411525 | 0.79 | SMN1; SMN2 (0.45) | POLBATMOPRM1SMN1; SMN2OPRD1 | |
| SCHEMBL21469230 | 0.79 | POLB (0.41) | POLBATMOPRM1SMN1; SMN2OPRD1 | |
| SCHEMBL5949812 | 0.79 | POLB (0.41) | POLBATMOPRM1SMN1; SMN2OPRD1 | |
| SCHEMBL15166991 | 0.78 | POLB (0.40) | POLBATMOPRM1SMN1; SMN2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101160049-B | Spiroketal-substituted cyclic ketoenols | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-05-11 | — | — | CN | disclosed |
| CN-103755716-A | Spiroketal-substituted cyclic ketoenols | BAYER CROPSCIENCE AG | 2014-04-30 | — | — | CN | disclosed |
| US-7999115-B2 | Spiro antibiotic derivatives | ACTELION PHARMACEUTICAL LTD. (SE) | 2011-08-16 | — | — | US | disclosed |
| US-20110190493-A1 | Spiroketal-Substituted Cyclic Ketoenols | BAYER CROPSCIENCE AG (DE) | 2011-08-04 | — | — | US | disclosed |
| US-7897543-B2 | Spiroketal-substituted cyclic ketoenols | BAYER CROPSCIENCE AG (DE) | 2011-03-01 | — | — | US | disclosed |
| CN-101885719-A | Spiroketal-substituted cyclic ketoenols | BAYER CROPSCIENCE AG | 2010-11-17 | — | — | CN | disclosed |
| CN-101885700-A | Spiroketal-substituted cyclic ketoenols | BAYER CROPSCIENCE AG | 2010-11-17 | — | — | CN | disclosed |
| CN-101863873-A | Spiroketal-substituted cyclic ketoenols | BAYER CROPSCIENCE AG | 2010-10-20 | — | — | CN | disclosed |
| EP-2066678-B1 | SPIRO ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-02-10 | — | — | EP | disclosed |
| US-20090270375-A1 | SPIRO ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-10-29 | — | — | US | disclosed |
| EP-2066678-A1 | SPIRO ANTIBIOTIC DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-10 | — | — | EP | disclosed |
| US-20080305955-A1 | Spiroketal-Substituted Cyclic Ketoenols | BAYER CROPSCIENCE AG (DE) | 2008-12-11 | — | — | US | disclosed |
| CN-101160049-A | Spiroketal-substituted cyclic ketoenols | BAYER CROPSCIENCE AG (DE) | 2008-04-09 | — | — | CN | disclosed |
| WO-2008026172-A1 | SPIRO ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-06 | — | — | WO | disclosed |
| US-6589976-B1 | Particularly effective wood preservation is achieved by impregnation processes on a large industrial scale, for example vacuum, a double vacuum or pressure processes. | BAYER AKTIENGESELLSCHAFT (DE) | 2003-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190493-A1 | Spiroketal-Substituted Cyclic Ketoenols | AKR1D1, PDHX, KHK | POLB 2370/4885ATM 4045/4885OPRM1 2534/4885 |
| US-20090270375-A1 | SPIRO ANTIBIOTIC DERIVATIVES | NR0B1, NRDC, NR4A1 | POLB 795/4885ATM 4075/4885OPRM1 410/4885 |
| US-20080305955-A1 | Spiroketal-Substituted Cyclic Ketoenols | AKR1D1, PDHX, KHK | POLB 2370/4885ATM 4045/4885OPRM1 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.